Last reviewed · How we verify
Consolidation Chemotherapy
Consolidation chemotherapy uses a combination of cytotoxic agents to eliminate residual cancer cells remaining after initial treatment and reduce the risk of disease relapse.
Consolidation Chemotherapy is a treatment regimen used in the management of certain cancers, particularly after initial therapy to eliminate any remaining cancer cells and reduce the risk of recurrence. This approach is often employed in hematological malignancies such as acute myeloid leukemia (AML) and multiple myeloma. The regimen typically involves a combination of chemotherapeutic agents tailored to the specific type and stage of cancer. While there is no FDA label for this specific regimen, it is widely used in clinical practice and supported by various institutional guidelines. The treatment is associated with significant side effects, including myelosuppression, infections, and gastrointestinal symptoms, which require careful monitoring and management.
At a glance
| Generic name | Consolidation Chemotherapy |
|---|---|
| Also known as | XEOLX*4 courses, XELOX, CAPOX, CTX, Ara-C |
| Sponsor | National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos |
| Drug class | Combination chemotherapy regimen |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Consolidation chemotherapy is administered after initial induction therapy to target any remaining malignant cells that may not have been eliminated by the first treatment phase. By using multiple cytotoxic agents with different mechanisms of action, this approach aims to maximize cell kill across heterogeneous cancer populations and improve long-term disease-free survival. The regimen is tailored based on cancer type, patient response to induction therapy, and individual tolerability factors.
Approved indications
- Acute leukemia (post-induction consolidation)
- Lymphoma (post-induction consolidation)
- Other hematologic malignancies requiring multi-phase chemotherapy
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia, anemia)
- Nausea and vomiting
- Mucositis
- Infection
- Hepatotoxicity
- Nephrotoxicity
- Cardiotoxicity
Key clinical trials
- Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma (PHASE3)
- Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (PHASE3)
- Durvalumab as Consolidation for Patients LS-SCLC (PHASE2)
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
- Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia (NA)
- A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma (PHASE2, PHASE3)
- Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer (PHASE2)
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: